| LRP2 Protein (Megalin) | |
|---|---|
| Protein Name | Megalin |
| Gene | LRP2 |
| UniProt | P98164 |
| Molecular Weight | ~600 kDa |
| Length | 4,630 amino acids |
| Cellular Location | Apical plasma membrane, Endosomes, Lysosomes |
| Expression | Kidney proximal tubules, Choroid plexus, Brain endothelium, Retina, Lung |
| Aliases | Megalin, GP330, LRP-2 |
LRP2, also known as Megalin, is one of the largest cell surface receptors in the human genome and belongs to the low-density lipoprotein receptor (LDLR) family. This multi-ligand scavenger receptor plays critical roles in endocytic uptake of diverse cargo molecules, including vitamins, lipids, hormones, and proteins. In the brain, Megalin is expressed primarily at the choroid plexus and brain microvascular endothelial cells, where it participates in blood-cerebrospinal fluid barrier (BCSFB) and blood-brain barrier (BBB) function. Recent research has implicated Megalin in the pathogenesis of neurodegenerative diseases, particularly Alzheimer's disease and Parkinson's disease, through its role in protein clearance and lipid metabolism.
Megalin is a type I transmembrane protein with an extraordinarily complex domain architecture:
The receptor undergoes constitutive recycling between the plasma membrane and endosomes, with a half-life of approximately 16 hours. At acidic pH in endosomes, ligands dissociate from Megalin, allowing for receptor return to the cell surface.
Megalin functions as a master scavenger receptor, mediating the cellular uptake of over 400 different ligands. In the kidney proximal tubules, Megalin is essential for reclaiming filtered proteins from the primary urine, preventing protein loss in the urine (proteinuria). Key ligands include:
At the choroid plexus, Megalin participates in the transport of nutrients from blood to cerebrospinal fluid (CSF) and the clearance of waste products from the central nervous system. The receptor mediates:
Megalin interacts with apolipoprotein E (ApoE) and other lipid-binding proteins, participating in brain lipid homeostasis. This function is particularly relevant given the strong genetic link between lipid metabolism dysfunction and Alzheimer's disease.
Multiple lines of evidence support a role for LRP2/Megalin in Alzheimer's disease pathogenesis:
Amyloid Clearance: LRP2 mediates the clearance of amyloid-beta (Aβ) peptides from the brain interstitium across the BBB and BCSFB. Decreased Megalin expression in aged brains and in AD patients may contribute to Aβ accumulation.
Tau Pathology: Recent studies have identified Megalin as a receptor for tau protein internalization and propagation. The receptor may facilitate the spread of pathological tau throughout the brain in AD.
ApoE Processing: As a receptor for ApoE, Megalin influences the processing of this major AD risk factor. Different ApoE isoforms (ApoE4 being the strongest genetic risk factor) show differential binding to Megalin.
Neuroinflammation: Megalin participates in the clearance of inflammatory mediators and immune complexes. Dysregulation may contribute to chronic neuroinflammation in AD.
LRP2 has also been implicated in Parkinson's disease:
Alpha-Synuclein Clearance: Emerging evidence suggests Megalin may mediate the uptake and clearance of alpha-synuclein, the protein that forms Lewy bodies in PD.
Iron Homeostasis: Megalin regulates iron metabolism through transferrin and ferritin uptake. Iron dysregulation is a well-established feature of PD pathogenesis.
Mitochondrial Function: The receptor interacts with proteins involved in mitochondrial quality control, and Megalin dysfunction may exacerbate mitochondrial deficits in dopaminergic neurons.
The strategic position of LRP2 at the blood-brain interfaces makes it an attractive target for therapeutic intervention:
Drug Delivery: Megalin-targeted drug conjugates are being developed to enhance drug delivery into the CNS. Apolipoprotein-based vectors exploit Megalin for brain targeting.
Gene Therapy: Viral vectors engineered with Megalin-binding domains can potentially cross the BBB more efficiently.
Small Molecule Modulators: Small molecules that enhance Megalin expression or function could boost amyloid and alpha-synuclein clearance.
Biomarker Potential: Soluble Megalin (sMegalin) in CSF is being investigated as a biomarker for BBB/BCSFB integrity in neurodegenerative diseases.
| Protein/Pathway | Interaction Type | Functional Consequence |
|---|---|---|
| ApoE | Receptor-ligand | Lipid transport, Aβ clearance |
| Amyloid-beta | Receptor-mediated endocytosis | Aβ clearance from brain |
| Transferrin | Receptor-ligand | Iron homeostasis |
| Clusterin (ApoJ) | Receptor-ligand | Chaperone, Aβ clearance |
| Dab2 | Adaptor protein | Clathrin-mediated endocytosis |
| ARH | Adaptor protein | Clathrin-mediated endocytosis |